48,830
edits
(→IHC) |
|||
Line 152: | Line 152: | ||
== Basal-like breast carcinoma== | == Basal-like breast carcinoma== | ||
*Overview | |||
**A category of breast carcinomas defined by gene expression profiling | *Overview:<ref>{{Cite journal | last1 = Badve | first1 = S. | last2 = Dabbs | first2 = DJ. | last3 = Schnitt | first3 = SJ. | last4 = Baehner | first4 = FL. | last5 = Decker | first5 = T. | last6 = Eusebi | first6 = V. | last7 = Fox | first7 = SB. | last8 = Ichihara | first8 = S. | last9 = Jacquemier | first9 = J. | title = Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. | journal = Mod Pathol | volume = 24 | issue = 2 | pages = 157-67 | month = Feb | year = 2011 | doi = 10.1038/modpathol.2010.200 | PMID = 21076464 }} | ||
**''Not used'' in clinical practice | </ref> | ||
**A category of breast carcinomas defined by gene expression profiling. | |||
**''Not used'' in clinical practice. | |||
**Somewhere between 15-30% of breast carcinomas. | **Somewhere between 15-30% of breast carcinomas. | ||
**Can be roughly be identified by immunohistochemistry - basal markers (CK14, p63, calponin, SMA) | **Can be roughly be identified by immunohistochemistry - basal markers (CK14, p63, calponin, SMA). | ||
**Not derived from myoepithelial cells, merely express a phenotype more in keeping with basal cells than ductal cells | **Not derived from myoepithelial cells, merely express a phenotype more in keeping with basal cells than ductal cells. | ||
**Most triple negative (ER, PgR, Her-2); therefore cannot be treated with the usual therapeutic agents | **Most triple negative (ER, PgR, Her-2); therefore cannot be treated with the usual therapeutic agents. | ||
**There is an association in young women between basal-like breast cancer and BRCA1 mutation. | **There is an association in young women between basal-like breast cancer and BRCA1 mutation. | ||
**Discussions of BRCA1 associated tumors, TNBC and BLBC are typically muddied by the overlap. | **Discussions of BRCA1 associated tumors, TNBC and BLBC are typically muddied by the overlap. | ||
**Increased incidence in some populations - African-Americans, young women | **Increased incidence in some populations - African-Americans, young women | ||
**Sporadic basal-like cancers do not have a BRCA1 mutation but may have a dysfunctional BRCA1 pathway. | **Sporadic basal-like cancers do not have a BRCA1 mutation but may have a dysfunctional BRCA1 pathway. | ||
**p53 mutations are frequent | **p53 mutations are frequent. | ||
*This molecular group includes a variety of morphologic phenotypes including: | *This molecular group includes a variety of morphologic phenotypes including: | ||
**High grade invasive ductal carcinoma of no special type. | **High grade [[invasive ductal carcinoma]] of no special type. | ||
**Medullary-like carcinoma (a carcinoma with some but not all the features of medullary carcinoma). | **Medullary-like carcinoma (a carcinoma with some but not all the features of medullary carcinoma). | ||
**Medullary | **[[Medullary breast carcinoma|Medullary carcinoma]] | ||
**Metaplastic | **[[Metaplastic breast carcinoma|Metaplastic carcinoma]]. | ||
**Adenoid cystic carcinoma | **[[Adenoid cystic carcinoma of the breast|Adenoid cystic carcinoma]]. | ||
**Secretory carcinoma | **[[Secretory carcinoma]]. | ||
*Classic morphological clues of a basal type cancer usually refer to medullary carcinoma features: | *Classic morphological clues of a basal type cancer usually refer to medullary carcinoma features: | ||
**Relatively circumscribed | **Relatively circumscribed. | ||
**Geographic necrosis | **Geographic necrosis. | ||
**Abundant mitoses | **Abundant mitoses. | ||
**Pushing margins | **Pushing margins. | ||
**Central fibrosis or necrosis | **Central fibrosis or necrosis. | ||
**High histological grade | **High histological grade. | ||
**Exceptionally high mitotic rate | **Exceptionally high mitotic rate. | ||
**Pushing borders | **Pushing borders. | ||
**Conspicuous lymphocytic infiltrate | **Conspicuous lymphocytic infiltrate. | ||
*Behaviour | *Behaviour: | ||
**Basal-like breast cancer is a heterogeneous group. | **Basal-like breast cancer is a heterogeneous group. | ||
**The behaviour of basal-like breast cancer appears to fall into two groups: | **The behaviour of basal-like breast cancer appears to fall into two groups: | ||
Line 199: | Line 200: | ||
Minireview: Basal-Like Breast Cancer: From Molecular Profiles to Targeted Therapies <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3035993/> | Minireview: Basal-Like Breast Cancer: From Molecular Profiles to Targeted Therapies <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3035993/> | ||
== Triple Negative Breast Carcinoma ==<ref>{{Cite journal | last1 = Badve | first1 = S. | last2 = Dabbs | first2 = DJ. | last3 = Schnitt | first3 = SJ. | last4 = Baehner | first4 = FL. | last5 = Decker | first5 = T. | last6 = Eusebi | first6 = V. | last7 = Fox | first7 = SB. | last8 = Ichihara | first8 = S. | last9 = Jacquemier | first9 = J. | title = Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. | journal = Mod Pathol | volume = 24 | issue = 2 | pages = 157-67 | month = Feb | year = 2011 | doi = 10.1038/modpathol.2010.200 | PMID = 21076464 }}</ref> | == Triple Negative Breast Carcinoma == | ||
Features:<ref name=pmid21076464>{{Cite journal | last1 = Badve | first1 = S. | last2 = Dabbs | first2 = DJ. | last3 = Schnitt | first3 = SJ. | last4 = Baehner | first4 = FL. | last5 = Decker | first5 = T. | last6 = Eusebi | first6 = V. | last7 = Fox | first7 = SB. | last8 = Ichihara | first8 = S. | last9 = Jacquemier | first9 = J. | title = Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. | journal = Mod Pathol | volume = 24 | issue = 2 | pages = 157-67 | month = Feb | year = 2011 | doi = 10.1038/modpathol.2010.200 | PMID = 21076464 }}</ref> | |||
**A category of breast carcinomas defined by immunohistochemical/FISH expression of ER, PR and HER2. | **A category of breast carcinomas defined by immunohistochemical/FISH expression of ER, PR and HER2. |
edits